Annexon Inc (ANNX) - News Archive

: This article summarises pivotal Phase 3 data presented by Annexon at the American Academy of Neurology’s 2025 Annual Meeting, reinforcing the potential of Tanruprubart (formerly ANX005) as a targeted therapy for Guill...

Overview of Inducement GrantsOn March 17, 2025, Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on developing innovative therapies for classical complement-mediated neuroinflammatory diseases, announce...

Annexon, Inc. Announces New Inducement Grants Amid Advancing Clinical MilestonesBRISBANE, Calif. Feb. 18, 2025 Annexon, Inc. (Nasdaq: ANNX), a pioneering biopharmaceutical company dedicated to transforming treatment opt...

Annexon, a biotechnology company focused on developing therapies for autoimmune and neurodegenerative diseases, recently announced promising topline results from a real-world evidence study comparing its innovative trea...

Annexon, Inc. Continues Strategic Talent Expansion with Recent Inducement Grants under Nasdaq Listing Rule 5635(c)(4)In a move indicative of its growth trajectory and commitment to addressing classical complement-mediat...

In a strategic move to bolster its workforce and accelerate its advancements in neuropharmaceutical treatments, Annexon, Inc. (Nasdaq: ANNX) announced the grant of inducement equity awards to seven new non-executive emp...

In a significant development for ophthalmology and the treatment of dry age-related macular degeneration (AMD), Annexon has announced plans to present new findings from its Phase 2 clinical trial of ANX007 at the upcomi...

Annexon Inc. Expands Workforce with Inducement Grants Amidst Promising Innovations in NeuroinflammationBrisbane, California - September 16, 2024 - In a strategic move reflecting robust growth and confidence in its innov...

Annexon Expands Senior Leadership to Accelerate Global Neuroinflammatory-Targeted PortfolioIn a move aimed at advancing its late-stage neuroinflammatory-targeted portfolio, Annexon, Inc. has bolstered its senior leaders...

In a recent press release, Annexon Inc (Nasdaq: ANNX) announced that it has granted inducements to two new non-executive employees under the 2022 Employment Inducement Award Plan. This news comes as the biopharmaceutica...

In recent developments within the field of ophthalmology, Annexon has made significant strides in the treatment of geographic atrophy (GA) associated with age-related macular degeneration (AMD). The company has official...

In an exciting development in the field of ophthalmology, Annexon Biosciences announced that they will present new, compelling Phase 2 clinical data on their investigational drug ANX007 at the upcoming 42nd Annual Scien...

Annexon Presents Positive Phase 3 Results for ANX005 in Guillain-Barr Syndrome at PNS Annual MeetingBrisbane, Calif. – At the annual meeting of the Peripheral Nerve Society (PNS) in 2024, Annexon Inc., a clinical-stage...

Innovative Biopharmaceutical Company, Annexon, Inc., Makes Strides in Developing Novel Therapies for Neuroinflammatory Diseases, Pricing their Public Offering at $6.25 per Share and Granting Inducement Awards to New Emp...

Annexon s C1q Blocking Antibody ANX005 Demonstrates Significant Efficacy in Pivotal Phase 3 TrialIn a landmark achievement that could revolutionize the treatment landscape for Guillain-Barré Syndrome (GBS), Annexon Bios...

Geographic Atrophy (GA), an advanced-stage disease at the dry end of Age-Related Macular Degeneration (AMD) affecting millions globally, has long awaited an effective treatment breakthrough. The search for a solution ma...

Annexon Continues to Attract Talent with Inducement Grants for New Employees: A Positive Sign for InvestorsAnnexon, Inc. (Nasdaq: ANNX), a leading biopharmaceutical company focused on developing innovative complement-ba...

Annexon, Inc., a renowned clinical-stage biopharmaceutical company, recently made an exciting announcement regarding the grant of an inducement award to a new non-executive employee. Under the provisions of the 2022 Emp...

Brisbane, Calif. - Annexon, Inc., a clinical-stage biopharmaceutical company focused on developing complement-based medicines for individuals battling severe inflammatory-related diseases, recently announced the awardin...

In a recent breakthrough, Annexon, a renowned biopharmaceutical company, has meticulously delineated its priorities for the year 2024, pivoting towards the milestone of late-stage clinical trials across its upstream com...